BIOMAT Database Logo BIOMAT Database Logo

Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment. 2021

Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Allergy Unit, IBIMA-Regional University Hospital of Málaga, ARADyAL, Málaga, Spain.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069444 Omalizumab An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. Xolair
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018927 Anti-Asthmatic Agents Drugs that are used to treat asthma. Anti-Asthmatic,Anti-Asthmatic Agent,Anti-Asthmatic Drug,Antiasthmatic,Antiasthmatic Agent,Antiasthmatic Drug,Anti-Asthmatic Drugs,Anti-Asthmatics,Antiasthmatic Agents,Antiasthmatic Drugs,Antiasthmatics,Agent, Anti-Asthmatic,Agent, Antiasthmatic,Agents, Anti-Asthmatic,Agents, Antiasthmatic,Anti Asthmatic,Anti Asthmatic Agent,Anti Asthmatic Agents,Anti Asthmatic Drug,Anti Asthmatic Drugs,Anti Asthmatics,Drug, Anti-Asthmatic,Drug, Antiasthmatic,Drugs, Anti-Asthmatic,Drugs, Antiasthmatic

Related Publications

Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.
March 2023, Tuberkuloz ve toraks,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Omalizumab: a treatment for severe asthma in real life?
January 2015, Revista portuguesa de pneumologia,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations.
May 2023, The Journal of asthma : official journal of the Association for the Care of Asthma,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients.
October 2018, Turkish thoracic journal,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Response to omalizumab in patients with severe allergic asthma: A real-life study.
October 2017, Respiratory medicine,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study.
January 2022, The open respiratory medicine journal,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Real life study of three years omalizumab in patients with difficult-to-control asthma.
January 2015, Allergologia et immunopathologia,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
November 2009, Respiratory medicine,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study.
January 2018, The World Allergy Organization journal,
Paloma Campo, and Gregorio Soto Campos, and Ana Moreira, and Santiago Quirce, and Alicia Padilla-Galo, and Eva Martínez-Moragón, and Aizea Mardones, and Ignacio Dávila
Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
May 2019, Allergy,
Copied contents to your clipboard!